/BNGO
BNGO Stock - Bionano Genomics, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$1.60+0.63%
+$0.01 (+0.63%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.27
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+400.0%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BNGO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.58 – $1.62
TARGET (TP)$8.00
STOP LOSS$1.47
RISK/REWARD1:49.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.34
52W High$22.80
52W Low$1.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $30.78M | $36.12M | $27.80M | $17.98M | $8.50M |
| Gross Profit | $380,000 | $9.57M | $5.95M | $3.87M | $2.77M |
| Gross Margin | 1.2% | 26.5% | 21.4% | 21.5% | 32.6% |
| Operating Income | $-103,983,000 | $-215,245,000 | $-131,698,000 | $-77,101,000 | $-38,551,000 |
| Net Income | $-112,017,000 | $-232,493,000 | $-132,596,000 | $-72,435,000 | $-41,106,000 |
| Net Margin | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% |
| EPS | $-88.13 | $-24508.80 | $-16505.40 | $-9421.20 | $-14194.80 |
Company Overview
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
60%
Hold / Neutral
2
40%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish2 Neutral/Bearish
Price Targets
$7
Average Target
↑ 306.3% Upside
Now
$4
Low
$7
Average
$12
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 15th 2024 | Ladenburg Thalmann | Downgrade | Neutral | - |
| September 10th 2024 | BTIG Research | Downgrade | Neutral | - |
| January 5th 2023 | Scotiabank | Initiation | Sector Outperform | $4 |
| December 12th 2022 | BTIG Research | Resumed | Buy | $3.5 |
| July 18th 2022 | Oppenheimer | Resumed | Outperform | $12 |
Earnings History & Surprises
BNGOBeat Rate
21%
Last 19 quarters
Avg Surprise
-1338.1%
EPS vs Estimate
Beats / Misses
4/14
1 met exactly
Latest EPS
$-1.59
Q4 2025
EPS Surprise History
Q1 24
-6508.0%
$-57.49vs$-0.87
Q2 24
-5514.1%
$-35.93vs$-0.64
Q3 24
-3321.4%
$-14.37vs$-0.42
Q4 24
-9023.8%
$-19.16vs$-0.21
Q1 25
-858.2%
$-57.49vs$-6.00
Q2 25
+67.0%
$-1.15vs$-3.49
Q3 25
+26.0%
$-1.99vs$-2.69
Q4 25
+12.2%
$-1.59vs$-1.81
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.82 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-1.81 | $-1.59 | +12.2% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-2.69 | $-1.99 | +26.0% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-3.49 | $-1.15 | +67.0% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-6.00 | $-57.49 | -858.2% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.21 | $-19.16 | -9023.8% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.42 | $-14.37 | -3321.4% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.64 | $-35.93 | -5514.1% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-0.87 | $-57.49 | -6508.0% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-44.91 | $-88.62 | -97.3% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-53.89 | $-74.25 | -37.8% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-53.89 | $-71.86 | -33.3% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-53.89 | $-77.84 | -44.4% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-71.86 | $-65.87 | +8.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-59.88 | $-65.87 | -10.0% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-47.90 | $-65.87 | -37.5% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-41.92 | $-47.90 | -14.3% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-35.93 | $-41.92 | -16.7% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-29.94 | $-35.93 | -20.0% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-29.94 | $-29.94 | 0.0% | = MET |
Latest News
Bionano Laboratories Gains 47% CMS Reimbursement Increase For OGM Blood-Cancer Test Code 81195 In 2026
📈 PositiveBenzinga•Dec 3, 2025, 01:06 PM
HC Wainwright & Co. Maintains Buy on Bionano Genomics, Lowers Price Target to $7
➖ NeutralBenzinga•Nov 24, 2025, 12:45 PM
Bionano Genomics Sees Q4 Sales $7.500M-$7.900M vs $8.072M Est
📉 NegativeBenzinga•Nov 13, 2025, 10:17 PM
Bionano Genomics Affirms FY2025 Sales Guidance of $26.000M-$30.000M vs $28.136M Est
➖ NeutralBenzinga•Nov 13, 2025, 10:16 PM
Bionano Genomics Q3 EPS $(1.59) Beats $(1.91) Estimate, Sales $7.367M Beat $6.871M Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:14 PM
Bionano Genomics Q3 Sales $7.367M Beat $6.871M Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:02 PM
Bionano Genomics Publishes Study Demonstrating That Optical Genome Mapping Can Overcome Key Limitations Of Targeted RNA-Sequencing Panels In Detecting Therapeutically Relevant Gene Rearrangements In Acute Leukemia
📈 PositiveBenzinga•Nov 6, 2025, 01:28 PM
Bionano Genomics Highlighted Expanding Role Of Optical Genome Mapping In Genetic Disease Research At ASHG Conference
📈 PositiveBenzinga•Oct 23, 2025, 12:07 PM
Bionano Genomics shares are trading lower after the company announced the pricing of a $10 million public offering.
📉 NegativeBenzinga•Sep 16, 2025, 03:08 PM
Bionano Genomics slides after pricing $10M equity offering
📉 NegativeSeeking Alpha•Sep 16, 2025, 01:28 PM
Bionano Genomics Prices $10M Public Offering Of 5M Shares And Series Warrants At A Combined Price Of $2.00; Could Potentially Earn $20M From Warrant Exercises
📉 NegativeBenzinga•Sep 16, 2025, 01:12 PM
BNGO stock has given up its prior gain. Bionano Laboratories shares were trading higher after the company announced that Centers for Medicare & Medicaid Services posted the preliminary payment determination for the Category I Current Procedural Terminology code for use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders.
➖ NeutralBenzinga•Sep 15, 2025, 04:26 PM
Bionano Laboratories shares are trading higher after the company announced that Centers for Medicare & Medicaid Services posted the preliminary payment determination for the Category I Current Procedural Terminology code for use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders.
📈 PositiveBenzinga•Sep 15, 2025, 03:56 PM
Bionano Genomics Welcomes CMS Preliminary Payment Determination For OGM Category I CPT Code Priced At $1.26K
📈 PositiveBenzinga•Sep 15, 2025, 11:10 AM
Bionano Genomics Selected For Sole Source Contract By NIH For Optical Genome Mapping Reagents And Instruments; No Contract Value Disclosed
📈 PositiveBenzinga•Sep 2, 2025, 03:43 PM
HC Wainwright & Co. Maintains Buy on Bionano Genomics, Raises Price Target to $11
📈 PositiveBenzinga•Aug 18, 2025, 11:27 AM
Bionano Genomics Posts Q2 Margin Gain
📈 PositiveThe Motley Fool•Aug 14, 2025, 08:43 PM
Bionano Genomics stock rises on Q1 revenue beat
📈 PositiveSeeking Alpha•May 14, 2025, 09:02 PM
Frequently Asked Questions about BNGO
What is BNGO's current stock price?
Bionano Genomics, Inc. (BNGO) is currently trading at $1.60 per share. The stock has moved +0.63% today.
What is the analyst price target for BNGO?
The average analyst price target for BNGO is $8.00, based on 1 analyst.
What sector is Bionano Genomics, Inc. in?
Bionano Genomics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is BNGO's market cap?
Bionano Genomics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does BNGO pay dividends?
No, Bionano Genomics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAIM
AIM ImmunoTech Inc.
$1.42
Mkt Cap: $0.0B
BNBX
BNB Plus Corp.
$2.51
Mkt Cap: $0.0B
GBS
GBS Inc.
$0.47
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
MYNZ
Mainz Biomed B.V.
$1.20
Mkt Cap: $0.0B
NDRA
ENDRA Life Sciences Inc.
$5.16
Mkt Cap: $0.0B
POAI
Predictive Oncology Inc.
$5.95
Mkt Cap: $0.0B
QNRX
Quoin Pharmaceuticals, Ltd.
$14.20
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
XTLB
XTL Biopharmaceuticals Ltd.
$0.82
Mkt Cap: $0.0B
Explore stocks similar to BNGO for comparison